Neisseria Meningitidis

9
Pipeline Programs
3
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
7
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
7 programs
2
5
Haemophilus influenzae type b- and meningococcalPhase 31 trial
Haemophilus influenzae type b- and meningococcal serogroup CPhase 31 trial
Hib-MenCY-TTPhase 31 trial
MenHibrixPhase 31 trial
MenitorixTMPhase 31 trial
+2 more programs
Active Trials
NCT00871338Completed284Est. Dec 2010
NCT00134719Completed1,104Est. Feb 2007
NCT00323050Completed468Est. Mar 2005
+4 more trials
M&
Merck & Co.RAHWAY, NJ
1 program
1
PR5IPhase 3
Sanofi
SanofiPARIS, France
1 program
1
PR5IPhase 31 trial
Active Trials
NCT01839188Completed385Est. Mar 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKHib-MenCY-TT
SanofiPR5I
GSKMenitorixTM
GSKMenHibrix
GSKHaemophilus influenzae type b- and meningococcal serogroup C
GSKHaemophilus influenzae type b- and meningococcal
GSKGSK2197870A
GSKMenHibrix

Clinical Trials (8)

Total enrollment: 4,402 patients across 8 trials

NCT01978093GSKHib-MenCY-TT

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Start: Feb 2014Est. completion: Mar 2016600 patients
Phase 3Completed
NCT01839188SanofiPR5I

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Start: May 2013Est. completion: Mar 2014385 patients
Phase 3Completed
NCT00891176GSKMenitorixTM

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Start: May 2009Est. completion: Nov 2012582 patients
Phase 3Completed
NCT00359983GSKMenHibrix

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Start: Sep 2006Est. completion: May 2011270 patients
Phase 3Completed
NCT00327184GSKHaemophilus influenzae type b- and meningococcal serogroup C

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Start: Apr 2006Est. completion: Nov 2006709 patients
Phase 3Completed
NCT00323050GSKHaemophilus influenzae type b- and meningococcal

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

Start: Nov 2004Est. completion: Mar 2005468 patients
Phase 3Completed
NCT00871338GSKGSK2197870A

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Start: Jun 2009Est. completion: Dec 2010284 patients
Phase 2Completed
NCT00134719GSKMenHibrix

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Start: Apr 2005Est. completion: Feb 20071,104 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space